January 21, 2026

The Honorable Bill Cassidy, M.D.
Chairman
U.S. Senate Committee on Health, Education, Labor & Pensions
455 Dirksen Senate Office Building
Washington, DC 20510

The Honorable Bernie Sanders
Ranking Member
U.S. Senate Committee on Health, Education, Labor & Pensions
332 Dirksen Senate Office Building
Washington, DC 20510

The Honorable Brett Guthrie
Chairman
U.S. House Committee on Energy & Commerce
2161 Rayburn H.O.B.
Washington, DC 20515

The Honorable Frank Pallone
Ranking Member
U.S. House Committee on Energy & Commerce
2107 Rayburn H.O.B.
Washington, DC 20515

RE: Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526)

Dear Chairman Cassidy, Chairman Guthrie, Ranking Member Pallone, Ranking Member Sanders:

Now that there has been bicameral, bipartisan introduction of the *Biosimilar Red Tape Elimination Act* by Representatives August Pfluger (R-TX) and Greg Landsman (D-OH) (H.R. 5526) as well as Senators Mike Lee (R-UT), Ben Ray Lujan (D-NM), Rand Paul (R-KY), and Maggie Hassan (D-NH) (S. 1954), on behalf of patients, providers, taxpayers, and consumers, we urge you to advance this crucial legislation. The *Biosimilar Red Tape Elimination Act* would remove the distinction between biosimilars and interchangeable biosimilars. In doing so, the legislation would increase patient access to essential biosimilar medications and reduce healthcare costs.

Since biosimilars first entered the market in 2015, they have generated savings of more than $56 billion and have been used in more than 3.3 billion days of patient therapy with no clinically meaningful differences in patient safety or outcomes. Further, biosimilar competition has expanded patient access by nearly 500 million days of therapy.

Unfortunately, the statutory distinction between biosimilars and interchangeable biosimilars continues to generate confusion and misinformation about the safety of biosimilar medicines. The Food and Drug Administration (FDA) has consistently affirmed that there is no scientific difference between biosimilars and interchangeable biologics. Most recently, FDA Commissioner Marty Makary, M.D., M.P.H., announced the Agency's intent to finalize guidance eliminating the requirement for switching studies and reiterated the FDA's recommendation that Congress remove this unnecessary distinction. The *Biosimilar Red Tape Elimination Act* is consistent with FDA's

science-based recommendation and represents an important step toward building confidence and streamlining patient access to biosimilar medicines.

We look forward to continuing to work with you, as leaders of the committees of jurisdiction, to achieve its enactment as soon as possible.

Sincerely,

Academy of Managed Care Pharmacy
AffirmedRx
AHIP
Allergy & Asthma Network
Alliance of Community Health Plans
Americans for Prosperity
American Society for Health-System Pharmacists
Blue Cross Blue Shield Association
Blue Shield of CA
Campaign for Sustainable Rx Pricing
CancerCare
Consumer Action
CVS Health
Economic Alliance for Michigan
Heartland Impact
Heritage Action for America
Kaiser Permanente
LIBRE Initiative
National Alliance of Healthcare Purchaser Coalitions
National Association of Chain Drug Stores
National Association of Hispanic Nurses
National Consumers League
National Hispanic Health Foundation
National Patient Advocate Foundation
Prime Therapeutics
Public Citizen
Public Sector HealthCare Roundtable
Spina Bifida Association
Taxpayers Protection Alliance
The Bipartisan Policy Center
The ERISA Industry Committee
The Heartland Institute
The Mended Hearts, Inc.
The R Street Institute
Transparency-Rx
U.S. PIRG
Washington Health Alliance